Novartis reports details on Zolgensma patient death, hires Saynor as Sandoz CEO

After reporting Phase III efficacy data a week ago for SMA therapy Zolgensma, Novartis unveiled details on a patient death suggesting that it may be linked to previous baseline respiratory complications. The pharma also said Wednesday in its 1Q19 earnings results that it hired Richard Saynor as CEO of its Sandoz unit.

Last week, the AveXis Inc. unit of Novartis AG

Read the full 609 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE